DXS International plc Trading Update
02 September 2022 - 4:00PM
UK Regulatory
TIDMDXSP
DXS INTERNATIONAL PLC
Trading Update
The Board of DXS International plc ("the Company"), the AQSE
Growth Market quoted healthcare information and digital clinical
decision support systems provider, is pleased to announce that the
Board is reviewing its growth plans for the next 24 months. The
Company is seeking to accelerate its current market expansion drive
in both the UK and internationally and to support the launch of its
new advanced artificial intelligence clinical decision support
solution. The option to achieve a rapid expansion of its customer
base may require further investment in its sales, marketing and
development base. A further fund raise to increase efforts in this
area is under consideration, and ideally the Company would like to
raise up to but not limited to GBP1.5m in this calendar year as a
part of those plans, however no firm decisions have yet been made
in this regard.
In our recent annual report, we highlighted that healthcare IT
is moving at an unprecedented pace. The Covid-19 pandemic has added
new impetus to the realisation that healthcare delivery is urgently
in need of a major overhaul and DXS, with deep knowledge and
experience in the electronic healthcare space, is well-positioned
to exploit this fast-emerging opportunity.
A further announcement will be made in due course when plans
have been finalised.
The Directors of DXS International plc accept responsibility for
this announcement.
Contacts :
David Immelman 01252 719800
DXS International plc
www.dxs-systems.com
AQSE Corporate Broker
Hybridan LLP 020 3764 2341
Claire Louise Noyce
Corporate Advisor
City & Merchant 020 7101 7676
David Papworth
Notes to Editors
About DXS:
DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other
trusted NHS sources, to doctors, nurses and pharmacists in their
workflow and during the patient consultation. This effective
clinical decision support ultimately translates to improved
healthcare outcomes delivered more cost effectively and which
should significantly contribute towards the NHS achieving its
projected efficiency savings.
(END) Dow Jones Newswires
September 02, 2022 02:00 ET (06:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
DXS (AQSE:DXSP)
Historical Stock Chart
From Apr 2024 to May 2024
DXS (AQSE:DXSP)
Historical Stock Chart
From May 2023 to May 2024